Magnetic Resonance Elastography for Liver Fibrosis in Methotrexate Treatment

Deana D. Hoganson, Jun Chen, Richard L. Ehman, Jayant A. Talwalkar, Clement J. Michet, Meng Yin, Cynthia S. Crowson, Eric L. Matteson

Department of Gas-troenterology and Hepatology, Mayo Clinic, Rochester, MN.
Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
Department of Radiology, Mayo Clinic, Rochester, MN.
Division of Rheumatology, Mayo Clinic, Rochester.
Division of Rheumatology, Mayo Clinic, Rochester.

DOI: 10.4236/ojra.2012.22003                

Abstract

Introduction: Hepatic magnetic resonance elastography (MRE) allows for noninvasive assessment of liver fibrosis. The purpose of this study was to evaluate the usefulness of MRE in detecting and quantifying liver fibrosis in patients with rheumatoid arthritis (RA) who have received methotrexate (MTX). Methods: The association between mean liver stiffness value as determined by MRE and variables of interest was determined. The decision for a liver biopsy in participants with an abnormal liver stiffness was made based on clinical judgment. Results: Sixty-five RA patients were enrolled. Mean liver stiffness value by MRE was abnormal in 7 patients, suggestive of hepatic injury. As a result of findings from the MRE, biopsies were performed in 5 patients and all correlated with elevated liver stiffness values. Elevated mean liver stiffness values were associated with body mass index (BMI) (OR = 1.18 per 1 kg/m²; 95% CI: 1.03, 1.36; p = 0.017). Neither the total MTX dose nor the duration of MTX treatment was associated with mean liver stiffness value (p = 0.51 and P = 0.20, respectively). Conclusion: MRE provides a reliable, non-invasive assessment of liver fibrosis in patients with RA receiving MTX. Patients with RA receiving MTX who have an elevated BMI may be at increased risk for chronic hepatic injury, regardless of MTX cumulative dose or duration of treatment.

Keywords

Methotrexate; Hepatic Magnetic Resonance Elastography; Liver Fibrosis; Rheumatoid Arthritis

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	T.R. Mikuls and J. O'Dell J. “The Changing Face Of Rheumatoid Arthritis Therapy: Results Of Serial Surveys,” Arthritis and Rheumatism Vol. 43, No. 2, 2000, pp. 464-465.
[2]	J. M. Kremer, G.S. Alarcon, R.W Lightfoot Jr., R.F. Wilkins, D.E. Furst, and H. J. Williams et. al. “Methotrexate For Rheumatoid Arthritis. Suggested Guidelines For Monitoring Liver Toxicity. American College of Rheumatology,” Arthritis and Rheumatism Vol. 37, No. 3, 1994, pp. 316-328.
[3]	J.M. Kremer, D.E. Furst, M.E. Weinblatt and S.D. Blotner SD. “Significant Changes In Serum AST Across Hepatic Histological Biopsy Grades: Prospective Analysis Of 3 Cohorts Receiving Methotrexate Therapy For Rheumatoid Arthritis,” Journal of Rheumatology Vol. 23, No. 3, 1996, pp. 459-461.
[4]	P. D. Kent, H.S. Luthra and C Michet C, Jr. “Risk Factors For Methotrexate-Induced Abnormal Laboratory Monitoring Results In Patients With Rheumatoid Arthritis,” Journal of Rheumatology Vol. 31, No. 9: 2004, pp. 1727-1731.
[5]	Y Yazici, D. Erkan, M.J. Harrison, N.P. Nikolov and S.A. Paget SA. “Methotrexate Use In Rheumatoid Arthritis Is Associated With Few Clinically Significant Liver Function Test Abnormalities,” Clinical and Experimental Rheumatology Vol. 23, No. 4, 2005, pp. 517-520.
[6]	Kremer JM. “Not Yet Time To Change The Guidelines For Monitoring Methotrexate Liver Toxicity: They Have Served Us Well,” Journal of Rheumatology Vol. 29, No. 8, 2002, pp. 1590-1592.
[7]	Angulo P. “Nonalcoholic Fatty Liver Disease,” New England Journal of Medicine Vol. 346, No. 16, 2002, pp. 1221-1231.
[8]	J. M. Kremer, R.G Lee and K.G. Tolman. “Liver Histology In Rheumatoid Arthritis Patients Receiving Long-Term Methotrexate Therapy. A Prospective Study With Baseline And Sequential Biopsy Samples,” Arthritis and Rheumatism Vol. 32, No. 2, 1989, pp. 121-127.
[9]	C.A. Phillips, P.J. Cera, T.F. Mangan and E.D. Newman. “Clinical Liver Disease In Patients With Rheumatoid Arthritis Taking Methotrexate,” Journal of Rheumatology Vol. 19, No. 2, 1992, pp. 229-233.
[10]	P.D. Hall, M.J. Ahern, L.R. Jarvis, P. Stoll, M.A. Jenner MA and H Harley. “Two Methods Of Assessment Of Methotrexate Hepatotoxicity In Patients With Rheumatoid Arthritis,” Annals of the Rheumatic Diseases Vol. 50, No. 7, 1991, pp. 471-476.
[11]	R.F. Willkens, P.A. Leonard PA, D.O. Clegg, K G Tolman, J R Ward, C R Marks, M L Greene, G J Roth, C G Jackson, and G W Cannon et. al. “Liver Histology In Patients Receiving Low Dose Pulse Methotrexate For The Treatment Of Rheumatoid Arthritis,” Annals of the Rheumatic Diseases, Vol. 49, No. 8, 1990, pp. 591-593.
[12]	S.G. West. Methotrexate Hepatotoxicity,” Rheumatic Diseases Clinics of North America, Vol. 23, No. 4, 1997, pp. 883-915.
[13]	Y. Yazici, T. Sokka, H. Kautiainen, C. Swearingen, I. Kulman and T. Pincus. “Long Term Safety Of Methotrexate In Routine Clinical Care: Discontinuation Is Unusual And Rarely The Result Of Laboratory Abnormalities,” Annals of the Rheumatic Diseases Vol. 64, No. 2, 2005, pp. 207-211.
[14]	P. Asbach, D. Klatt, U. Hamhaber, J. Braun, R. Somasundaram, B. Hamm and I. Sack. “Assessment Of Liver Viscoelasticity Using Multifrequency MR Elastography,” Magnetic Resonance Medicine Vol. 60, No. 2, 2008, pp. 373-379.
[15]	L Huwart, C. Sempoux, E. Vicaut, N. Salameh, L. Annet, E. Danse, F. Peeters, L.C. ter Beek, J. Rahier, R. Sinkus, Y. Horsmans and BE Van Beers. “Magnetic resonance elastography for the noninvasive staging of liver fibrosis,” Gastroenterology Vol. 135, No. 1, 2008, pp. 32-40.
[16]	O. Rouviere, M. Yin, M.A. Dresner, L.J. Burgart, J. L. Fidler and R.L. Ehman. “MR Elastography Of The Liver: Preliminary Results,” Radiology Vol. 240, No. 2, 2006, pp. 440-448.
[17]	J. A. Talwalkar. “Elastography For Detecting Hepatic Fibrosis: Options And Considerations,” Gastroenterology Vol. 135, No. 1, 2008, pp. 299-302.
[18]	M. Yin, J.A. Talwalkar, K.J. Glaser, A. Manduca, R. C. Grimm, P. J. Rossman, J. L. Fidler, and R. L. Ehman. “Assessment Of Hepatic Fibrosis With Magnetic Resonance Elastography,” Clinics in Gastroenterology and Hepatology Vol. 5, No. 10, 2007, pp. 1207-1213 e2.
[19]	S.H. Park, J.Y. Choe and S.K. Kim. “Assessment Of Liver Fibrosis By Transient Elastography In Rheumatoid Arthritis Patients Treated With Methotrexate,” Joint Bone Spine Vol. 77, No. 6, 2010, pp. 588-592.
[20]	A.M. Walker, D. Funch, N.A. Dreyer, K.G. Tolman, J.M. Kremer, G.S. Alarcon, R.G. Lee and M.E. Weinblatt. “Determinants Of Serious Liver Disease Among Patients Receiving Low-Dose Methotrexate For Rheumatoid Arthritis,” Arthritis and Rheumatism, Vol. 36, No. 3, 1993, pp. 329-335.
[21]	Q.E. Whiting-O'Keefe, K.H. Fye and K.D. Sack. “Methotrexate And Histologic Hepatic Abnormalities: A Meta-Analysis,” American Journal of Medicine, Vol. 90, No. 6, 1991, pp. 711-716.
[22]	W.J. Shergy, R.P. Polisson, D.S. Caldwell, J.R. Rice, D.S. Pisetsky and N.B. Allen. “Methotrexate-Associated Hepatotoxicity: Retrospective Analysis Of 210 Patients With Rheumatoid Arthritis,” American Journal of Medicine, Vol. 85, No. 6, 1988, pp. 771-774.
[23]	B.A. Neuschwander-Tetri and S.H. Caldwell. “Nonalcoholic Steatohepatitis: Summary Of An AASLD Single Topic Conference,” Hepatology, Vol. 37, No. 5, 2003, pp. 1202-1219.
[24]	J. Jou, S.S. Choi and A.M. Diehl. “Mechanisms Of Disease Progression In Nonalcoholic Fatty Liver Disease,” Seminars in Liver Disease, Vol. 28, No. 4, 2008, pp. 370- 379.
[25]	G. Langman, P.M. Hall and G. Todd. “Role Of Non-Alcoholic Steatohepatitis In Methotrexate-Induced Liver Injury,” Journal of Gastroenterology and Hepatology, Vol. 16, No. 12, 2001, pp. 1395-1401.
[26]	R.S. Azfar, J.M. Gelfand. “Psoriasis And Metabolic Disease: Epidemiology And Pathophysiology,” Current Opinion in Rheumatology, Vol. 20, No. 4, 2008, pp. 416-422.
[27]	H.H. Roenigk, Jr., R. Auerbach, H. Maibach, G. Weinstein and M. Lebwohl. “Methotrexate In Psoriasis: Consensus Conference,” Journal of the American Academy of Dermatology, Vol. 38, No. 3, 1998, pp. 478-485.